Completed PHASE2/PHASE3 INTERVENTIONAL NCT00277251

Alendronate Osteoporosis Study

Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis

Sponsor: Boston Children's Hospital

Conditions Glucocorticoid-Associated Osteopenia and Osteoporosis

Interventions Alendronate

Updated 7 times since 2017 Last updated: Apr 10, 2017 Started: Mar 31, 2003 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Glucocorticoid-Associated Osteopenia and Osteoporosis and is currently completed. Boston Children's Hospital leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Sep 2020 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Unknown Status → Completed
Jan 2017 — May 2017 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston Children's Hospital
Elizabeth Glaser Pediatric AIDS Foundation
Glaser Pediatric Research Network

Data source: Boston Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.